Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Muscle Invasive Bladder Cancer (MIBC) 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Docetaxel 7Trastuzumab 3sargramostim 2entrectinib 2Radiotherapy 2Polymerase Chain Reaction 2Immunohistochemistry 2Gene Expression Profiling 2Fluorodeoxyglucose F18 2Flow Cytometry 2Erlotinib Hydrochloride 2Biopsy 2zanidatamab 1vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab deruxtecan 1tipifarnib 1tanespimycin 1pertuzumab 1pembrolizumab 1oncogene protein E7, Human papillomavirus type 16 1entinostat 1alectinib 1aldesleukin 1X-Ray Therapy 1Vorinostat 1Thalidomide 1Taxes 1Ritonavir 1Quality of Life 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × zanidatamab × Genitourinary × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡